Cold Spring Harbor Laboratory, GSK to develop diabetes and obesity therapeutic
Scientists at CSHL and GSK will pursue drug development based on a novel approach to regulate the enzymatic activity of the phosphatase PTP1B. The goal of the multi-year CSHL-GSK collaboration is to identify potent, selective, orally bioavailable small molecules that inhibit PTP1B activity in vivo following stimulation by insulin and leptin, which would be expected to overcome insulin and leptin resistance that is encountered in diabetes and obesity.
"At CSHL, we are striving to achieve mutually beneficial and effective collaborations to accelerate research and develop new therapies to benefit patients," said Teri Willey, vice president for business development and technology transfer at CSHL. Obesity and diabetes are among the major medical challenges that society currently faces. According to the International Diabetes Federation, diabetes had a worldwide prevalence of 366 million in 2011 and that is predicted to increase to 552 million by 2030. In the U.S. alone, the annual health cost related to obesity is nearly $200 billion.
The work at CSHL will be led by Professor Nicholas Tonks, who is experienced with the protein tyrosine phosphatase (PTP) family of enzymes and their roles in human diseases. He is considered a pioneer in the PTP field, having discovered PTP1B. His work was instrumental in establishing the importance of the PTP family of enzymes as regulators of how cells respond to stimuli from their environment and as potential therapeutic candidates for several human diseases.
GSK and CSHL will provide project co-leadership, allowing synergy between their different sets of expertise to facilitate the development of novel therapeutics.